Sec Form 4 Filing - Zinda Michael @ Repare Therapeutics Inc. - 2020-12-16

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Zinda Michael 2. Issuer Name and Ticker or Trading Symbol Repare Therapeutics Inc. [ RPTX] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) EVP, Chief Science Officer (Last) (First) (Middle) C/O REPARE THERAPEUTICS INC., 7210 FREDERICK-BANTING, SUITE 100 3. Date of Earliest Transaction (MM/DD/YY) 12/16/2020 (Street) ST-LAURENT, A8H4S 2A1 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 12/16/2020 M 6,876 A $ 1.637 92,105 D Common Stock 12/16/2020 M 2,080 A $ 1.637 94,185 D Common Stock 12/16/2020 S 8,022 D $ 35.17 ( 1 ) 86,163 D Common Stock 12/16/2020 S 934 D $ 36.01 ( 2 ) 85,229 D Common Stock 12/18/2020 M 8,321 A $ 2.062 93,550 D Common Stock 12/18/2020 S 8,121 D $ 34.59 ( 3 ) 85,429 D Common Stock 12/18/2020 S 200 D $ 35.1 ( 4 ) 85,229 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Employee Stock Option (right to buy) $ 1.637 12/16/2020 M 6,876 ( 5 ) 06/14/2027 Common Stock 6,876 $ 0 4,122 D Employee Stock Option (right to buy) $ 1.637 12/16/2020 M 2,080 ( 6 ) 12/04/2027 Common Stock 2,080 $ 0 29,538 D Employee Stock Option (right to buy) $ 2.062 12/18/2020 M 8,321 ( 7 ) 03/29/2029 Common Stock 8,321 $ 0 85,707 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Zinda Michael C/O REPARE THERAPEUTICS INC. 7210 FREDERICK-BANTING, SUITE 100 ST-LAURENT, A8H4S 2A1 EVP, Chief Science Officer Signatures /s/ Steve Forte, Attorney-in-Fact 12/18/2020 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to$35.753 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities andExchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth infootnotes (1), (2), (3) and (4). ( 2 )The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.23 inclusive. ( 3 )The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.02 to $34.99 inclusive. ( 4 )The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.05 to $35.15 inclusive. ( 5 )Twenty-five percent (25%) of the shares subject to the option vested on June 14, 2018, and one thirty-sixth (1/36th) of the remaining shares subject to the option vested or shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date. ( 6 )Twenty-five percent (25%) of the shares subject to the option vested on June 22, 2018, and one thirty-sixth (1/36th) of the remaining shares subject to the option vested or shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date. ( 7 )Twenty-five percent (25%) of the shares subject to the option vested on March 29, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to the option vested or shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.